Skip to Main Content

Author’s note: On Thursday, April 11, the plaintiff who filed the shareholder lawsuit against Taysha Gene Therapies withdrew the suit “without prejudice,” according to an updated filing with Delaware’s Chancery court. No other details were provided.

I regret being caught unaware of the suit’s dismissal prior to publishing the article below. The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, remains an unsettled question, but for now, it’s not one that’s being adjudicated in a court case at this time.

advertisement

The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, is now a legal question.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.